Skip to main content
TipRanks
Go Ultimate75% OFF

Pak Fah Yeow International Limited (0239) AI Stock Analysis

2 Followers
HK:0239

Pak Fah Yeow International Limited

(HKEX:0239)

Select Model
Rating:82Outperform
Price Target:HKD 3.00â–²(28.76% Upside)
Action:reiterated
Date:11/06/26

The company's exceptional financial health, marked by high profitability, a debt-free balance sheet, and strong cash generation, is the primary driver of the score. This is complemented by a highly attractive valuation with a low P/E and a substantial dividend yield. Technical trends are supportive, with the stock trading above key moving averages and exhibiting positive momentum.

Positive Factors
Conservative Balance SheetVery low leverage gives the company substantial financial flexibility and limits balance-sheet risk. A stable equity base also supports resilience through weaker periods, while allowing management to fund property-related activities without depending heavily on borrowing or refinancing.
Negative Factors
Revenue VolatilityRepeated year-to-year revenue declines make the company’s top-line trajectory less predictable and can reduce visibility into future earnings. For a property-focused business, uneven revenue can also make operating performance and cash generation fluctuate across reporting periods.

Pak Fah Yeow International Limited (0239) vs. iShares MSCI Hong Kong ETF (EWH)

-5%0%5%10%15%HK:0239+5.00%EWH+4.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 724.56M
Dividend Yield
8.58%
Average Volume (3M)
59.96K
Price to Earnings (P/E)
7.3
Beta (1Y)
-0.06
Revenue Growth
10.63%
EPS Growth
39.44%
Country
Hong Kong
Employees
100
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Pak Fah Yeow International Limited Business Overview & Revenue Model

Company Description

Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Sout...

Pak Fah Yeow International Limited Financial Statement Overview

Summary

Strong profitability with net margin of 42.7% and expanding EBIT margin. Exceptional balance sheet with near-zero debt and high equity. Robust cash flow exceeding net income. Revenue decline in recent years is a minor concern.

Income Statement

80Positive

Balance Sheet

95Very Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue220.18M213.88M236.91M259.31M147.20M139.82M
Gross Profit140.54M133.14M203.20M167.59M74.06M68.71M
EBITDA133.21M115.35M105.73M136.81M45.90M54.67M
Net Income98.95M91.35M78.63M105.04M29.95M38.19M
Balance Sheet
Total Assets878.30M828.37M843.35M907.47M823.14M837.75M
Cash, Cash Equivalents and Short-Term Investments400.27M344.54M290.02M277.61M180.34M178.28M
Total Debt6.95M6.87M4.20M4.74M5.50M16.21M
Total Liabilities144.25M105.63M111.45M142.28M115.91M130.03M
Stockholders Equity734.04M722.75M731.91M765.18M707.23M707.72M
Cash Flow
Free Cash Flow91.38M112.33M78.02M144.84M39.76M69.54M
Operating Cash Flow97.80M112.77M78.96M147.90M39.92M70.36M
Investing Cash Flow-5.78M-63.29M-3.19M16.65M-6.67M-565.00K
Financing Cash Flow-57.60M-57.67M-67.54M-48.96M-33.91M-22.41M

Pak Fah Yeow International Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price2.33

Price Trends

50DMA2.40Negative
100DMA2.36Negative
200DMA2.30Positive

Market Momentum

MACD-0.02Positive
RSI33.40Neutral
STOCH5.42Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0239, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 2.42, below the 50-day MA of 2.40, and above the 200-day MA of 2.30, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.40 is Neutral, neither overbought nor oversold. The STOCH value of 5.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0239.

Pak Fah Yeow International Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:0239 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:0239HK:023982OutperformHKD 726.12M7.2613.59%8.58%10.63%39.44%
HK:2161HK:216177OutperformHKD 1.22B5.9218.70%11.55%6.69%2.45%
HK:2348HK:234874OutperformHKD 1.30B4.806.78%7.33%6.55%36.62%
HK:2633HK:263370OutperformHKD 1.69B5.8913.26%10.16%-0.47%-0.40%
HK:0897HK:089759NeutralHKD 401.18M100.000.34%―-8.30%-44.44%
HK:0570HK:057058NeutralHKD 5.46B-4.47-4.98%0.32%-15.80%-298.94%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%HK:0239HK:0570HK:0897HK:2161HK:2348HK:2633Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:0239 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:0239Pak Fah Yeow International Limited2.330.125.43%
HK:0570China Traditional Chinese Medicine Holdings Co 1.08-1.23-53.03%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.06-14.29%
HK:2161JBM (Healthcare) Ltd.1.48-1.31-46.93%
HK:2348Dawnrays Pharmaceutical Holdings Ltd.0.86-0.24-21.89%
HK:2633Jacobson Pharma Corporation Limited0.89-0.35-28.17%

Pak Fah Yeow International Limited Corporate Events

Pak Fah Yeow boosts interim profit and dividends on healthcare growth

Aug 20, 2026

Pak Fah Yeow International Limited reported interim results for the six months ended 30 June 2026 showing a 6.7% year-on-year increase in revenue to HK$101.0 million and a 3.7% rise in underlying recurring profit, driven mainly by stronger sales from...

Pak Fah Yeow Declares Interim and Special Dividends for 2026

Aug 20, 2026

Pak Fah Yeow International Limited, incorporated in Bermuda and listed on the Hong Kong Stock Exchange, operates in the consumer healthcare sector with a focus on medicated oils and related wellness products. The board is led by Chairman Gan Wee Sean...

Pak Fah Yeow Declares Interim Dividend for First Half of 2026

Aug 20, 2026

Pak Fah Yeow International Limited, a Hong Kong‑listed healthcare and consumer products company, derives its business from the regional market, with shares quoted on the Main Board under stock code 00239. The board comprises a mix of executive, non‑e...

Pak Fah Yeow Declares Special Interim Dividend for First Half of 2026

Aug 20, 2026

Pak Fah Yeow International Limited, a Hong Kong-listed consumer healthcare company known for its medicated oils and topical remedies, generates steady cash flow from its established brands in regional markets. Its defensively positioned business and...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026